Pfizer (PFE) Completes Acquisition of ReViral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Pfizer Completes Acquisition of ReViral
June 9, 2022 10:00 AM EDTAcquisition expands Pfizers anti-infective pipeline and reinforces commitment to developing both medicines and vaccines to help combat respiratory syncytial virus (RSV)
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and... More



